Tvardi Therapeutics, Inc.
NCM: TVRDLive Quote
About Tvardi Therapeutics, Inc.
Healthcare
Biotechnology
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
📊 Fundamental Analysis
Tvardi Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -237.8%, which indicates that capital utilization is currently under pressure.
At a current price of $2.90, TVRD currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $2.75 - $43.65).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$26.88M
Trailing P/E
--
Forward P/E
-1.11
Beta (5Y)
--
52W High
$43.65
52W Low
$2.75
Avg Volume
54K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App